摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-4-(4-fluoro-phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydro-pyridine-3-carboxylic acid {5-[1-(2-hydroxy-ethyl)-5-methyl-1H-pyrazol-3-yl]-2-methyl-phenyl}-amide | 1232888-79-7

中文名称
——
中文别名
——
英文名称
(S)-4-(4-fluoro-phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydro-pyridine-3-carboxylic acid {5-[1-(2-hydroxy-ethyl)-5-methyl-1H-pyrazol-3-yl]-2-methyl-phenyl}-amide
英文别名
(4S)-4-(4-fluorophenyl)-N-[5-[1-(2-hydroxyethyl)-5-methylpyrazol-3-yl]-2-methylphenyl]-1-methyl-2-oxo-3,4-dihydropyridine-5-carboxamide
(S)-4-(4-fluoro-phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydro-pyridine-3-carboxylic acid {5-[1-(2-hydroxy-ethyl)-5-methyl-1H-pyrazol-3-yl]-2-methyl-phenyl}-amide化学式
CAS
1232888-79-7
化学式
C26H27FN4O3
mdl
——
分子量
462.524
InChiKey
GROJYQRDZJYGQK-NRFANRHFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    34
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    87.5
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS
    申请人:Berger Jacob
    公开号:US20100160384A1
    公开(公告)日:2010-06-24
    Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
    化合物的公式I:或其药用盐,其中m、n、p、q、R1、R2、R3、R4、R5和R6如本文所定义。还公开了制备这些化合物的方法,并将这些化合物用于治疗与P2X7嘌呤受体相关的疾病。
  • US8163929B2
    申请人:——
    公开号:US8163929B2
    公开(公告)日:2012-04-24
  • [EN] DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS<br/>[FR] AMIDES DE DIHYDROPYRIDONE UTILES COMME MODULATEURS DE P2X7
    申请人:HOFFMANN LA ROCHE
    公开号:WO2010072607A1
    公开(公告)日:2010-07-01
    Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, p, q, R1, R2, R3, R4, R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.
查看更多